07 - HCT Practice Guidelines for MDS, Pt. 1: Risk Stratification and Eligibility

In this two-part episode, Zachariah DeFilipp, MD, and Andrew Brunner, MD, with Massachusetts General Hospital discuss their findings on a committee of the American Society for Transplantation and Cellular Therapy (ASTCT) to publish an evidence-based review on guidelines for the use of allogeneic hematopoietic cell transplantation in the management and treatment of myelodysplastic syndromes (MDS) from the perspective of both transplant and hematology/oncology.

In Part I: Risk Stratification and Eligibility, experts discuss the goals of the guidelines review, the latest research, advances in MDS risk stratification and eligibility criteria, and best practices for patients with different presentations of MDS.

To read bios on the panelists and to access additional resources related to this episode, visit Our Site.